Use of our “model system”—namely PBMCs of patients—clearly demonstrates that impairment of CD8+ cell function does not happen only in the vicinity of the tumor: it can downregulate the KCa3.1 channels even at a distant location from the tumor to assure for itself survival. The gene discussed is CD8A; the disease is neoplasm.